What is claimed:

1. An oral dosage form comprising Drotaverine or a salt thereof, preferably Drotaverine hydrochloride, and an ion exchange resin, wherein Drotaverine and the ion-exchange resin comprise a Drotaverine-ion-exchange complex, and wherein the dosage form is formulated as an orally disintegrating tablet.

2. The oral dosage form of claim 1, wherein drotaverine unbound to resin does not exceed 2% w/w, preferably does not exceed 1% w/w.

3. An oral dosage form comprising Drotaverine or a salt thereof, preferably Drotaverine hydrochloride, and a taste enhancer, wherein the dosage form is formulated as an orally disintegrating tablet, wherein the dosage form optionally further comprises a bitter masking flavor.

4. The oral dosage form of any of claims 1-3, wherein the dosage form comprises 2.5-100 mg Drotaverine or a salt thereof.

5. The oral dosage form of claim 3 or 4, further comprising an ion exchange resin, wherein Drotaverine and the ion-exchange resin comprise a Drotaverine-ion-exchange complex.

6. The oral dosage form of claim 1 or 5, wherein the ion-exchange resin is Kyron 114, Kyron 314, Indion 204, Indion 234, Indion 294, or a combination thereof; and/or wherein the ratio of Drotaverine to ion-exchange resin is 1:2 to 1:6; and/or wherein the oral dosage form is in the form of granules, wherein the size of the granules is in the range of around 850 microns to 300 microns.

7. The oral dosage form of any one of claims 1-6, wherein the dosage form has a hardness of 3-12 kp.

8. The oral dosage form of any one of claims 1-7, wherein the dosage form disintegrates in the mouth in 60 seconds or less without water, preferably in 30 seconds or less without water; and/or wherein the dosage form disintegrates in 1-3 mL of water in 60

seconds or less, preferably in 30 seconds or less.

9. The oral dosage form of any one of claims 1-8, wherein the dosage form further comprises excipients selected from a diluent, a disintegrant, a flavoring agent, a sweetener, a lubricant, a glidant, an anti-adherent, or a combination thereof.

10. The oral dosage form of any one of claims 1 or 5-9, wherein the ratio of excipients to drug-resin complex is from 0.05:1 to 2.5:1, preferably from 0.1:1 to 2:1.

11. The oral dosage form of any one of claims 1-10, wherein the dosage form further comprises at least one diluent, wherein the diluent comprises a monosaccharide, an oligosaccharide, a polysaccharide, a lactose, a sugar alcohol, a cellulose powder, a microcrystalline cellulose, a silicified microcrystalline cellulose, a derivative of cellulose modified chemically, a starch, or a combination thereof; and/or
wherein the dosage form further comprises at least one disintegrant, wherein the disintegrant comprises at least one of a starch, natural or chemically modified cellulose, microcrystalline cellulose, gum, alginic acid or salt thereof, sugar, aluminum oxide, or a synthetic polymer, preferably wherein the level of disintegrant is in the amount of 1% to 10% w/w and more preferably 2% to 8% w/w; and preferably wherein the starch is sodium starch glycollate, and/or the natural or chemically modified cellulose is croscarmellose sodium; and/or. the synthetic polymer is crospovidone; and/or
wherein the dosage form further comprises at least one flavoring agent, wherein the flavoring agent comprises a strawberry flavor, a cherry flavor, an orange flavor, a peppermint flavor, a black currant flavor, a banana flavor, a raspberry flavor, a red fruit flavor, a wild berry flavor, a caramel flavor, or a combination thereof; and/or
wherein the dosage form further comprises at least one sweetener, wherein the sweetener comprises aspartame, potassium acesulfame, sodium saccharinate, neohesperidine dihydrochalcone, sucralose, sucrose, fructose, monoammonium glycyrrhizinate, or a combination thereof; and/or
wherein the dosage form further comprises at least one lubricant, wherein the lubricant comprises sodium benzoate, sodium stearyl fumarate, calcium stearate, magnesium stearate, zinc stearate, glyceryl behenate, stearic acid, glyceryl monostearate, or a combination thereof.

12. An oral dosage form comprising Drotaverine or a salt thereof, Kyron 114, *microcrystalline cellulose, colloidal silicon dioxide, mannitol, fructose, sucralose, aspartame, crospovidone, sodium stearyl fumarate, fruit flavoring, and bitter masking flavoring, wherein* the dosage form is formulated as an orally disintegrating tablet.

13. The oral dosage form of any one of claims 1-12, wherein the dosage form is stable for three months when stored at 40° C and 75% RH as accelerated storage conditions, preferably wherein the dosage form is stable for six months when stored at 40° C and 75% RH as accelerated storage conditions.

14. The oral dosage form of any one of claims 1-13, wherein the dosage form is stable for three months when stored at 25-30° C temperature and 60-75% RH as long-term storage conditions, preferably wherein the dosage form is stable for six months when stored at 25-30° C temperature and 60-75% RH as long-term storage conditions, and more preferably wherein the dosage form is stable for two years when stored at 25-30° C temperature and 60-75% RH as long-term storage conditions.

15. The oral dosage form of any one of claims 1-14, wherein the oral dosage form exhibits improved taste and/or improved aftertaste and/or improved palatability.

16. A method of preparing an orally disintegrating tablet of Drotaverine or salt thereof comprising:

a. mixing an ion-exchange resin with water;
b. adding Drotaverine or salt thereof to the ion-exchange resin dispersion of Step-a mixture to form a drug-resin complex by stirring for sufficient time;
c. The filtered drug-resin complex was washed with water until the filtrate obtained after washing until unbound Drotaverine drug content is less than 2.0%.
d. drying the drug-resin complex to form a dried drug-resin complex which should contain less than 5.0% w/w water content;
e. Milling and sieving the dried drug-resin complex to obtain drug-resin complex granules of appropriate size;
f. separately weighing the drug-resin complex granules and at least one excipient;

g. passing the drug-resin complex granules and excipient through a mesh;

h. blending the drug-resin complex granules and excipient; and subsequently mixed with disintegrant, flavoring agent, sweetener, lubricant, glidant, an anti-adherent.

i. The final blended drug-resin complex granules and excipients are thereafter compressed into as orally disintegrating tablets.

17. The method of claim 16 wherein the ion-exchange resin comprises Kyron 114, Kyron 314, Indion 204, Indion 234, Indion 294; and/or

wherein ion-exchange resin is mixed with water for 30-45 minutes, then Drotaverine is added slowly and mixed for at least 2-4 hours; and/or

wherein the ion-exchange resin and Drotaverine or salt thereof are mixed in a ratio of 2:1 to 6:1; and/or

wherein the drug-resin complex is air dried or dried using drying equipment; and/or

wherein the dried drug-resin complex has less than 5.0% w/w of water; and/or

wherein the dried drug-resin complex is sieved through a mesh, wherein the mesh is no larger than 850 microns; and/or

wherein the drug-resin complex granules and excipient are mixed for 10-20 minutes; and/or

wherein the orally disintegrating tablet is formed using direct compression, dry granulation, wet granulation, or fluidized bed preparation methods.

18. The dosage form of any one of claims 1-15 or the method of claim 16 or 17, wherein at least 90% of the orally disintegrating tablet is dissolved in five minutes *in vitro* using a paddle at 40 RPM in 0.1 N HCl dissolution media.

19. The oral dosage form of any one of claims 1-15 for use in treating abdominal pain in a subject.

20. Use of an oral dosage form of any one of claims 1-15 in the manufacture of a medicament for treating abdominal pain in a subject in need thereof.